A detailed history of Silverarc Capital Management, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Silverarc Capital Management, LLC holds 167,110 shares of ITCI stock, worth $14.3 Million. This represents 3.04% of its overall portfolio holdings.

Number of Shares
167,110
Previous 192,345 13.12%
Holding current value
$14.3 Million
Previous $13.2 Million 7.24%
% of portfolio
3.04%
Previous 3.74%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $1.72 Million - $2.04 Million
-25,235 Reduced 13.12%
167,110 $12.2 Million
Q2 2024

Aug 14, 2024

BUY
$64.76 - $79.84 $10.2 Million - $12.6 Million
157,538 Added 452.6%
192,345 $13.2 Million
Q1 2024

May 14, 2024

SELL
$64.37 - $75.65 $2.91 Million - $3.42 Million
-45,193 Reduced 56.49%
34,807 $2.41 Million
Q4 2023

Feb 14, 2024

SELL
$46.37 - $73.65 $5.97 Million - $9.48 Million
-128,730 Reduced 61.67%
80,000 $5.73 Million
Q3 2023

Nov 13, 2023

BUY
$52.09 - $64.1 $521,264 - $641,448
10,007 Added 5.04%
208,730 $10.9 Million
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $4.03 Million - $4.9 Million
73,688 Added 58.93%
198,723 $12.6 Million
Q1 2023

May 15, 2023

SELL
$43.8 - $56.99 $671,497 - $873,713
-15,331 Reduced 10.92%
125,035 $6.77 Million
Q4 2022

Feb 14, 2023

BUY
$44.07 - $54.45 $186,856 - $230,868
4,240 Added 3.11%
140,366 $7.43 Million
Q3 2022

Oct 28, 2022

SELL
$42.7 - $59.99 $7.59 Million - $10.7 Million
-177,836 Reduced 56.64%
136,126 $6.33 Million
Q2 2022

Jul 25, 2022

BUY
$43.0 - $65.64 $221,149 - $337,586
5,143 Added 1.67%
313,962 $17.9 Million
Q1 2022

May 13, 2022

BUY
$38.74 - $62.09 $4.41 Million - $7.07 Million
113,819 Added 58.37%
308,819 $18.9 Million
Q4 2021

Feb 14, 2022

BUY
$35.2 - $53.42 $3.28 Million - $4.97 Million
93,110 Added 91.38%
195,000 $10.2 Million
Q3 2021

Nov 15, 2021

SELL
$28.72 - $42.49 $326,488 - $483,026
-11,368 Reduced 10.04%
101,890 $3.8 Million
Q2 2021

Aug 16, 2021

SELL
$29.3 - $44.5 $493,968 - $750,225
-16,859 Reduced 12.96%
113,258 $4.62 Million
Q1 2021

May 18, 2021

SELL
$30.8 - $39.51 $2.15 Million - $2.76 Million
-69,883 Reduced 34.94%
130,117 $4.42 Million
Q4 2020

Feb 16, 2021

BUY
$23.34 - $32.22 $4.67 Million - $6.44 Million
200,000 New
200,000 $6.36 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.08B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.